Highlights

• LifeCycle Pharma A/S (Copenhagen:LCP) today announced the Interim Report for the 9 months ended September 30, 2009 and reported in line with expectations a net loss of DKK 211.2 million for the first nine months of 2009, compared to a net loss of DKK 69.1 million for the same period in 2008. During the first nine months of 2009 LCP recognized DKK 2.3 million in revenues compared to DKK 165.3 million in the same period of 2008. Revenue in 2008 includes DKK 152 million up-front payment in connection with the sale of the future royalty stream from Fenoglide(R).

• For the first nine months of 2009, LCP's research and development costs amounted to DKK 164.4 million compared to DKK 192.2 million during the same period in 2008.

• On September 30, 2009, LCP had cash and cash equivalents of DKK 392.1 million.

• Positive LCP-Tacro(TM) results have been obtained from a completed 12 month extension phase of the Phase 2 clinical study of LCP-Tacro(TM) tablets in stable liver transplant patients. These new data demonstrated that LCP-Tacro(TM) tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf(R).

• On August 31, 2009, LCP announced that the Board of Directors of LCP and Jim New, President & CEO, had agreed to terminate the contract with Jim New. Until a new CEO has been identified, Paul Edick, Chairman of the Board of LCP, and Dr. Thomas Dyrberg, Deputy Chairman of the Board, will, upon request from the Board of Directors, assume such specific assignments for the Company, which are necessary to ensure LCP's continual and uninterrupted business together with the management of LCP. The search for a new CEO is ongoing.

• The recruitment of patients is progressing in the Phase 3 study for LCP-Tacro(TM) in stable kidney patients and now approximately 80% are enrolled compared to 50% enrolled in the previous quarter. At the same time the preparation of the phase 3 protocol for LCP-Tacro(TM) in de novo kidney patients is in its final stage and is expected to be submitted to the U.S. Food and Drug Administration (FDA) before the year-end.

• The full year outlook for 2009 is improved once again. LCP now expects an operating loss in the range of DKK 290 - 310 million and a net loss in the range of DKK 280 - 300 million. LCP's cash position is expected to be in the range of DKK 300 - 330 million at year-end 2009.

A conference call will be held tomorrow, November 12, 2009 at 2.30 PM CET (Denmark). Please refer to page 7 for further details.

Interim report for the 9 Months Ended September 30, 2009